

SCOPE: ALS, CCT	
MEDICATION:	ONDANSETRON (Zofran)
INTERVENTION:	<p><u>Classification:</u> Antiemetic</p> <p><u>Actions:</u> Blocks serotonin; mechanism not fully characterized</p> <p><u>Contraindications:</u></p> <ul style="list-style-type: none"> • Hypersensitivity <p><u>Precautions:</u></p> <ul style="list-style-type: none"> • Hepatic disease • Lactation • Hypersensitivity including anaphylaxis and bronchospasm • QT prolongation happens in a dose dependent manor <p><u>Dosage:</u></p> <ol style="list-style-type: none"> I. <u>Nausea & Vomiting:</u> <ol style="list-style-type: none"> a. Adult: <ol style="list-style-type: none"> i. IV/IO/IM: 4 mg; may repeat every 10 min, max total dose 16 mg b. Pediatric: <ol style="list-style-type: none"> i. IV/IO: 0.1 mg/kg , max single dose 4 mg, may repeat every 10 min x3 <p><u>Onset of Action:</u> 10 minutes</p> <p><u>Duration:</u> 4-6 hours</p> <p><u>Adverse Effects:</u> Headache, constipation, fatigue, drowsiness, fever, dizziness, anxiety, cold/warm sensation, rash, urinary retention, paresthesia, bradycardia, tachycardia, risk of prolonged QT intervals</p> <p><u>Special Considerations:</u></p> <ol style="list-style-type: none"> I. Use caution when administering Zofran to a patient with prolonged-QT

If this is a patient care policy, the information contained herein is used to provide guidance in the care of patients, but should not, and does not replace or preclude the use of clinical judgment.

<i>FOR OFFICE USE ONLY</i>	
Originator:	Original Date:
Revised Date:	
Effective Date: 06/01/18	Page 1 of 1